ORIGINAL ARTICLE

What role may symptoms play in the diagnosis of airflow limitation?

A study in an elderly population

ASTRI MEDBØ & HASSE MELBYE

Institute of Community Medicine, University of Tromsø, Tromsø, Norway

Abstract

Background. Chronic obstructive pulmonary disease (COPD) is an under-diagnosed condition. General practitioners meet and examine the patients in early stages of the disease, and symptoms represent the starting point of the diagnostic process. Aim. To evaluate the diagnostic value of respiratory symptoms in the diagnosis of airflow limitation. Methods. Spirometry was performed in a cross-sectional population-based study of 3954 subjects 60 years and older (54.5% women), who also filled in a questionnaire on symptoms. Results. The prevalence of any airflow limitation was 15.5% and 20.8%, in women and men, respectively, whereas the corresponding prevalence of severe airflow limitation (FEV₁ < 50% predicted) was 3.4% and 4.9%. The positive predictive value of chronic cough with phlegm for any airflow limitation was 37.0% in women and 40.4% in men, and 17.3% and 14.2%, respectively, for severe airflow limitation. Wheezing was a symptom which persisted despite smoking cessation, whereas coughing was considerably less common in ex-smokers than in current smokers. Wheezing, dyspnoea on unhurried walking, dyspnoea on quick walking, and coughing with phlegm were independent predictors of any airflow limitation, OR 1.5, 1.8, 1.4, and 1.6 respectively. (The ORs for severe airflow limitation were 2.4, 2.4, 2.4, and 1.6 respectively.) To be an ex-smoker (OR 2.4) or a current smoker (OR 5.8) was of greater importance. In never- and ex-smokers the chance of having airflow limitation was almost doubled when having two or more, compared with one, of the three symptoms: wheezing, dyspnoea, and coughing with phlegm. Ex-smokers reporting two symptoms had a similar risk of airflow limitation to current smokers not reporting any symptoms. Conclusion. Respiratory symptoms are valuable predictors of airflow limitation and should be emphasized when selecting patients for spirometry.

Key Words: Airflow limitation, COPD, elderly, family practice, spirometry, symptoms

Chronic obstructive pulmonary disease (COPD) is well known as a leading cause of morbidity and mortality in the developed countries worldwide [1–4]. The criteria for diagnosing COPD are, by definition, based on spirometry in the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria [1], and in other guidelines [5–7]. FEV₁/FVC <70% post-bronchodilator is the criterion for diagnosing COPD [1], regardless of age and symptoms. The one-dimensioned grading, based on spirometry only, is an item for discussion [8–10].

It is well known that smokers are at risk of getting COPD [1], and the prevalence of the disease increases with increasing age [9,10]. Dyspnoea is known as the hallmark symptom of COPD and is often the reason for seeking a doctor [1,11], whereas chronic cough may be the first symptom in the

- Respiratory symptoms are important clues in the diagnosis of airflow limitation in the elderly, and should be emphasized when selecting patients for spirometry.
- In general practice there should be a low threshold for doing spirometry in current smokers.
- This study has demonstrated that lung function testing also should be kept in mind in ex-smokers with respiratory symptoms.

development of COPD [1]. Assessments of symptoms are, however, subjective and can be evaluated in different ways. Symptoms are often underreported by patients and not recognized by physicians,

(Received 29 November 2007; accepted 26 February 2008) ISSN 0281-3432 print/ISSN 1502-7724 online © 2008 Taylor & Francis DOI: 10.1080/02813430802028938

Correspondence: Astri Medbø, Institute of Community Medicine, University of Tromsø, NO-9037 Tromsø, Norway. E-mail: astri.medbo@ism.uit.no

especially in the early stages of COPD [12]. A weak correlation between reduced FEV_1 and patients' symptoms has been demonstrated in evaluation of pulmonary rehabilitation [12,13]. Improvements in dyspnoea after such rehabilitation could not be detected by spirometric tests [12].

We wanted to evaluate the diagnostic value of respiratory symptoms in the elderly, and the potential role a combination of symptoms in the diagnosis of airflow limitation might have. Our aim was increased insight regarding symptoms as guide for general practitioners in the diagnosis of COPD. We have argued for new criteria of COPD after the age of 70 years [10], and in this paper we have defined airflow limitation to occur only when FEV₁/FVC < 65% for subjects 70 years and older.

Material and methods

Subjects

The survey took place in Tromsø, a city in the northern part of Norway, with about 61 000 inhabitants, and 7842 inhabitants aged 60 years or more (as at January 2001). There is little occupational or environmental pollution in Tromsø. The survey started in March 2001 and ended in February 2002 [10].

Among subjects aged 60 years or more, a total of 5328 subjects were eligible, and 4519 (85%) took part [10]. Spirometry was performed in 4102 subjects, 90% of the attendees and 77% of the eligible. Absence of staff and technical problems were reasons for spirometry not being performed in 10% of the attendees.

Questionnaire

A questionnaire including smoking habits and different symptoms and diseases was sent by mail together with the invitation to participate. The questions concerning respiratory symptoms were the following: Wheezing: Have you experienced episodes with wheezing in your chest? Dyspnoea: Do you get dyspnoeic when (1) You walk quickly on level ground or slightly upwards? (2) You walk unhurriedly on level ground? Coughing: Do you cough daily in periods of the year? If yes: (1) Do you usually bring up phlegm with the cough? (2) Did you have such a cough for more than three months during the last two years? Participants answering positively to all three questions concerning cough were defined as having chronic cough with phlegm. The answers to all the questions were yes, or no. The questions are based on the MRC questionnaire on respiratory symptoms [14].

Examinations

Spirometry was carried out with the use of one spirometer only, a "Sensormedics Vmax 20". The American Thoracic Society criteria for spirometry testing [15] were followed. Calibration of the instrument was performed every morning and at the machine's demand. Three trained technicians shared the conducting of the spirometry. The subjects were sitting, using a nose clip, and were instructed to blow for as long as possible, and for at least six seconds. At least three exhalations were required. The difference between best and next best FEV_1 and FVC should not exceed 5% or 200 ml, whichever was the greater. A reversibility test was not performed. Current drug therapy was not interrupted before the test. Height was measured barefoot.

In week 41 and 42 in 2001 an inter- and intraobserver agreement test was done with two of our three technicians (A and B) and 80 participants. It implied repeated testing in both weeks. The two technicians were blinded to each other's results. Kappa values ranged from 0.77 to 0.92 (mean 85.5) [10].

Statistical analysis

Spirometric results were analysed according to sex, age, smoking habits, and reported symptoms. Any airflow limitation was defined as: $FEV_1/FVC < 70\%$ for subjects under 70 years of age, and $FEV_1/FVC <$ 65% for subjects 70 years and older [10]. Severe airflow limitation was defined as: When in addition $FEV_1 < 50\%$ was predicted, by using a Norwegian reference value [16]. Differences in prevalence were evaluated by chi-squared statistics. Binary logistic regression was used in calculating odds ratios (OR). A three-symptom score was made based on the independent predictors determined by logistic regression. Each symptom gave 1 + when present, and zero when absent. Positive predictive values (PPV) for airflow limitation of separate symptoms, and the three-symptom score were calculated. ROC curves were used to illustrate the value of the three symptoms in the diagnosis of airflow limitation. The SPSS 14.0 for Windows (SPSS Inc., Chicago, Illinois, USA) was used in the statistical analyses.

The Regional Committee for Medical Research Ethics approved the study. All the participants gave informed written consent.

Results

Spirometry was performed in 4102 persons aged 60 years or more, 2269 women and 1833 men. At the completion of the data collection, 25 women and 12 men had withdrawn their consent to participate.

94 A. Medbø & H. Melbye

Table I. Characteristics of the 3954 participants in the study.

	Women		Men	
	n	%	n	%
Total	2154	54.5	1800	45.5
Age (years)				
60–69	1152	53.5	957	53.2
70–79	889	41.3	748	41.6
80+	113	5.2	95	5.3
Smoking habit ¹				
Never smoker	999	46.9	327	18.3
Ex-smoker	633	29.7	1043	58.3
Current smoker	498	23.4	419	23.4
Body mass index (BMI)				
<30	1636	76.0	1492	82.9
≥30	518	24.0	308	17.1
Airflow limitation				
Any airflow limitation ²	333	15.5	375	20.8
Severe airflow limitation ³	73	3.4	88	4.9
Reported symptoms				
Wheezing	483	22.4	437	24.3
Dysphoea on unhurried walking	88	4.1	55	3.1
Dyspnoea on quick walking	1044	48.5	834	46.3
Daily cough in periods	346	16.1	407	22.6
Daily cough with phlegm	227	10.5	295	16.4
Chronic cough with phlegm	127	5.9	183	10.2

Notes: ¹Missing data in 24 women and 11 men. ²Defined as FEV1/FVC <70% for persons 69 years and younger and FEV1/FVC <65% for persons 70 years and older. ³In addition FEV1 < 50% predicted according to the equation of Langhammer.

Ninety women and 21 men (2.7% of the total) were excluded due to inadequate performance (of these 84 women and 20 men blew for less than three seconds) [10], and a total of 2154 women aged 60– 89 and 1800 men aged 60–85 years were included in the analysis (Table I). The material has been described in more details in a previous paper [10]. Significantly more women (47%) than men (18%) were never smokers (p < 0.001). The prevalence of any airflow limitation was 15.5% in women and 20.8% in men. The corresponding prevalence of severe airflow limitation was 3.4% and 4.9%, respectively (Table I). Wheezing and two levels of dyspnoea were reported with about the same frequencies in women and men, but men did more often report cough, with and without phlegm, than women (Table I). Wheezing was reported significantly more frequently in ex- and current smokers than in never-smokers (Table II). In men, dyspnoea on quick walking was reported significantly less frequently in never smokers compared with ex-smokers. This symptom was more common in never-smoking women than in never-smoking men. Among those with $BMI \ge 30$, never-smoking women reported both forms of dyspnoea more frequently than did never-smoking men (on unhurried walking 8.6% versus 1.8%, on quick walking 65.0% versus 40.4%). Reporting cough, with or without phlegm, was significantly more common in current smokers than in ex-smokers, and more common in smoking men than in smoking women.

The PPVs of coughing, in any form, for any airflow limitation, were higher in men than in women (Table III). Cough with phlegm had higher PPV for severe airflow limitation in women than in men, although women had lower prevalence of this condition (Tables I and III). The independent role of sex, age, smoking status, and the different symptoms for airflow limitation is shown in Table IV. Four significant symptoms had ORs between 1.4 and 1.8 for any airflow limitation, and between 1.6 and 2.4 for severe airflow limitation. Current smoking had the highest OR for both airflow limitation categories (5.8 and 3.3, respectively). A three-symptom-score based on the significant symptoms in Table IV, wheezing, dyspnoea (either on unhurried or quick walking), and daily cough with phlegm was calculated, and positive predictive values of the scores according to smoking status are given in Table V. Among subjects with no symptoms 5.1% never smokers and 31.2% current smokers had airflow limitation. In never smokers and ex-smokers the risk of having any airflow limitation increased by 2-3 times at between one and two symptoms. Exsmokers with two or three symptoms had a similar risk of any airflow limitation to all current smokers,

Table II. Frequency of reported symptoms (%) by smoking status in 2130 women and 1789 men aged 60 years or more.

	Women			Men			
Reported symptoms	Never smoker	Ex-smoker ¹	Smoker ²	Never smoker	Ex-smoker ¹	Smoker ²	
Wheezing	16.8	25.8 ^{p=0.000}	29.3 $^{p=0.202}$	11.9	22.7 ^{p=0.000}	37.7 p = 0.000	
Dyspnoea on unhurried walking	4.1	3.9 p = 1.000	4.2 p = 0.880	1.5	$3.0^{p=0.232}$	4.3 p = 0.202	
Dyspnoea on quick walking	45.7	$50.7 p^{-0.053}$	$51.4^{p=0.857}$	33.3	$47.3^{p=0.000}$	53.7 $^{p=0.028}$	
Daily cough in periods	12.3	$13.6^{p} = 0.449^{0.449}$	26.9 p = 0.000	15.0	17.8 p = 0.274	40.3 p = 0.000	
Daily cough with phlegm	6.4	9.6 $p = 0.022$	20.1 p = 0.000	10.1	13.2 p = 0.150	28.9 p = 0.000	
Chronic cough with phlegm	2.9	$6.0^{p=0.003}$	11.8 p = 0.001	6.7	$7.9^{p=0.551}$	18.1 p = 0.000	

Notes: 1p-values: Ex-smokers are compared with never smokers. 2p-values: Smokers are compared with ex-smokers.

Table III. Positive predictive value (PPV) of reported symptoms for any airflow limitation¹ and severe airflow limitation¹ for 2154 women and 1800 men 60 years and older.

	Any airflow limitation Severe airflo			ow limitation	
Reported symptoms	Women PPV (%)	Men PPV (%)	Women PPV (%)	Men PPV (%)	
Wheezing	25.5	32.7	9.7	10.5	
Dyspnoea on unhurried walking	30.7	36.4	15.9	16.4	
Dyspnoea on quick walking	18.7	27.2	5.6	8.2	
Daily cough in periods	26.6	35.4	10.1	10.8	
Daily cough with phlegm	31.7	40.0	14.5	11.9	
Chr. cough with phlegm	37.0	40.4	17.3	14.2	

Notes: See notes 2 and 3 to Table I, respectively.

31.2% and 35.3%, respectively, whereas never smokers did not reach this risk even with a full score of symptoms. In all smoking groups the risk of severe airflow limitation increased by any increase in symptom score.

The ROC curves of the symptoms score for airflow limitation and severe airflow limitation gave areas under curve of 0.63 and 0.76, respectively (Figure 1).

Discussion

Symptoms play an important role and should be emphasized when searching for airflow limitation in the elderly. The risk of any airflow limitation is considerable in ex-smokers with two or more respiratory symptoms, as it is in all current smokers. The risk of severe airflow limitation increases exponentially by increasing amount of symptoms in both ex-smokers and current smokers. The study confirms what is known from previous epidemiological studies [1,12,17–20]: that smoking is a strong contributor to both respiratory symptoms and airflow limitation.

Wheezing was a common symptom and was reported in 22-24% of all our participants, and significantly less frequently in those who were never smokers compared with ex- and current smokers (see Tables I and II). It was found to be an independent predictor of any airflow limitation (see Table IV). Vandevoorde et al. [20] also found wheezing to be strongly linked to COPD. It was the only sign to be significantly more frequent in heavily smoking men with COPD (50%) than in heavily smoking men without COPD (26.9%). Van Schayck et al. [17] found in their review paper cough, phlegm, dyspnoea, and wheezing as discriminating symptoms in COPD (OR 2.4-3.6). Freeman et al. [21] found the best questions discriminating for COPD were age, dyspnoea on exertion, and wheezing.

Reporting dyspnoea on unhurried walking was rarely reported (3-4%), and there were no significant differences in never smokers compared with exsmokers or current smokers (see Table II). However, this symptom turned out to be an important predictor of any airflow limitation, with the highest OR of the four significant symptoms.

Table IV. Odds ratios (OR), with 95% confidence intervals (CI), of gender, age, smoking status, and symptoms, in the development of any airflow limitation and severe airflow limitation, in 3919 subjects aged 60 years or more.

	Any airflow limitation		Severe airflow limitation		
	OR	95% CI	OR	95% CI	
Male gender	1.2	1.0–1.4	1.1	0.8–1.6	
Age over 70	1.0	1.0-1.0	1.1	1.0 - 1.1	
Ex-smoker	2.4	1.9-3.1	2.4	1.4 - 4.0	
Current smoker	5.8	4.5-7.5	3.3	1.9-5.6	
Wheezing	1.5	1.2-1.8	2.4	1.7-3.5	
Dyspnoea on unhurried walking	1.8	1.2-2.6	2.4	1.4 - 4.1	
Dyspnoea on quick walking	1.4	1.1-1.6	2.4	1.6-3.6	
Daily cough	1.1	0.8-1.5	1.3	0.8 - 2.2	
Daily cough with phlegm	1.6	1.1 - 2.4	1.6	0.9-3.0	
Chronic cough with phlegm	1.2	0.8 - 1.7	1.4	0.8–2.5	

Notes: See notes 2 and 3 to Table I, respectively.

Table V. The risk of having any airflow limitation	or severe airflow limitati	on ¹ according to number of sympton	ms (wheezing, both forms
of dyspnoea, and cough with phlegm), according to	o smoking status, in 3919	subjects aged 60 years or more (wor	nen and men are analysed
together).			

		Never smokers		Ex smokers			Current smokers		
Number of symptoms	n	Moderate to severe airflow limitation (%)	Severe airflow limitation (%)	n	Moderate to severe airflow limitation (%)	Severe airflow limitation (%)	n	Moderate to severe airflow limitation (%)	Severe airflow limitation (%)
0	688	5.1	0.6	735	10.6	1.1	317	31.2	2.8
1	443	6.3	1.6	556	15.6	2.9	293	32.4	4.4
2	155	15.5	4.5	295	27.1	10.5	201	36.8	9.5
3	40	15.0	5.0	90	44.4	20.0	106	52.8	22.6

Note: See notes 2 and 3 to Table I, respectively.

Never-smoking women with $BMI \ge 30$ reported being breathless more often than never-smoking men, on both unhurried and quick walking. Obese subjects have an enhanced perception of dyspnoea [22]. Smokers usually have lower BMI than the general population [23]. Overweight may be an explanation for over-reporting breathlessness in never-smoking women. When a normal weight patient reports dyspnoea on unhurried walking, the doctor has a particular reason to consider airflow limitation.

Reporting dyspnoea when walking quickly on level ground or slightly upwards was very common (see Tables I and II). Almost half of all our participants report this symptom, regardless of sex or smoking status, except for never-smoking men. Vrijhoef et al. [18] regarded breathlessness in moderate and heavy smokers as an early sign of COPD. The patients in their study were few and very selected, and hard to compare with our survey. All our participants were 60 years and older. Dyspnoea is usually more prominent in the elderly [11]. GOLD [1] considers dyspnoea as a hallmark symptom, and Ries [12], who deals with dyspnoea in a review article, says: "Yet in the primary care setting, even a few simple questions related to the presence and extent of dyspnoea may yield substantial diagnostic and prognostic information". Among the elderly, however, dyspnoea on quick walking as the only symptom seems to be of limited discriminating value when searching for airflow limitation.

In our study coughing in any form had PPVs for any airflow limitation of 26.6–37.0% in women, and 35.4–40.4% in men, and was more common in men than in women, irrespective of smoking status (see Table II). All types of coughing were significantly



Figure 1. Diagnostic values of a three-symptom score for any airflow limitation and severe airflow limitation for women and men together. Note: AUC = area under curve.

more common in smokers than in ex-smokers and never smokers (see Table II). Calverley et al. [24] found similar frequencies of coughing to ours: chronic cough in 5.3% of non-COPD and 13.6% of COPD patients. They considered wheeze and phlegm to be the two most important symptoms in the diagnosis of COPD. To report cough, especially with phlegm, may be viewed to be not very feminine and therefore reported less by females. It was interesting that coughing with phlegm in our study was a stronger predictor of severe airflow limitation in women than in men (see Table III), despite a lower reporting rate of the condition. Phlegm was also an important symptom according to Holleman et al. [19]. In their review paper, wheezing, coughing, and sputum production were the most important symptoms of airflow limitation. Geijer et al. also found coughing to be independently associated with the presence of mild COPD [25].

Lindberg et al. [26] followed a Swedish population for 10 years, to determine the cumulative incidence of COPD. They evaluated respiratory symptoms prior to the development of COPD, and found that those who developed COPD during the 10-year period reported significantly more symptoms at the start of the survey than those who did not develop COPD. The GOLD COPD stage 0, defined as "at risk": "Chronic cough and sputum production; lung function is still normal" [1], has been removed in the latest version [4]. Although there are limited data supporting the relation between development of COPD and people at risk [27,28], the exclusion of stage 0 can be questioned. Excluding symptoms may reduce the GP's attention towards the clinical presentation when considering COPD.

The omission of reversibility testing is a weakness of our study, which we have discussed previously [10]. Not all subjects with moderate airflow limitation have COPD. That is why we have chosen to use the term airflow limitation in this study. Further examinations are needed before the diagnosis of COPD can be established.

In conclusion, respiratory symptoms are important clues in the diagnosis of airflow limitation in the elderly. In general practice there should be a low threshold for undertaking spirometry in current smokers. This study has demonstrated that lung function testing should also be kept in mind in exsmokers with respiratory symptoms.

Acknowledgements

The survey was funded by the University of Tromsø, the National Health Screening Service, and the Lung Fund, Department of Pulmonology, University Hospital of North Norway. Thanks are offered to all the inhabitants of Tromsø City who participated in this survey and to the three spirometry technicians Anne Britt Larssen, Liv Kirsti Jørgensen, and Eva Solstad.

References

- Claude Lenfant, Nikolai Khaltaev editors. Global initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO workshop report. 2701. 2005. National Institutes of Health, National Heart, Lung, and Blood Institute; 2001.
- [2] Sullivan SD, Buist AS, Weiss K. Health outcomes assessment and economic evaluation in COPD: Challenges and opportunities. Eur Respir J 2003;21:1S–3S.
- [3] Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.
- [4] Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55.
- [5] Pierson DJ. Clinical practice guidelines for chronic obstructive pulmonary disease: A review and comparison of current resources. Respir Care 2006;51:277–88.
- [6] BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(Suppl 5):S1–28.
- [7] Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ ERS position paper. Eur Respir J 2004;23:932–46.
- [8] Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006;27:822–32.
- [9] Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002;20:1117–22.
- [10] Medbo A, Melbye H. Lung function testing in the elderly: Can we still use FEV(1)/FVC <70% as a criterion of COPD? Respir Med 2007;101:1097–1105.
- [11] Pedersen F, Mehlsen J, Raymond I, Atar D, Skjoldborg US, Hildebrandt PR. Evaluation of dyspnoea in a sample of elderly subjects recruited from general practice. Int J Clin Pract 2007;61:1481–91.
- [12] Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: The role of dyspnea. Am J Med 2006;119: 12–20.
- [13] Chapman KR. The needs of patients with COPD can be met by more aggressive treatment of symptoms. Prim Care Resp J 2002;11:15–19.
- [14] Questionnaire on Respiratory Symptoms (1986). Medical Research Council; 1986.
- [15] Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152: 1107–36.
- [16] Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Forced spirometry reference values for Norwegian adults: The Bronchial Obstruction in Nord-Trondelag Study. Eur Respir J 2001;18:770–9.
- [17] Van Schayck CP, Halbert RJ, Nordyke RJ, Isonaka S, Maroni J, Nonikov D. Comparison of existing symptombased questionnaires for identifying COPD in the general practice setting. Respirology 2005;10:323–33.

98 A. Medbø & H. Melbye

- [18] Vrijhoef HJ, Diederiks JP, Wesseling GJ, van Schayck CP, Spreeuwenberg C. Undiagnosed patients and patients at risk for COPD in primary health care: Early detection with the support of non-physicians. J Clin Nurs 2003;12:366–73.
- [19] Holleman DR Jr, Simel DL. Does the clinical examination predict airflow limitation? JAMA 1995;273:313–9.
- [20] Vandevoorde J, Verbanck S, Gijssels L, et al. Early detection of COPD: A case finding study in general practice. Respir Med 2007;101:525–30.
- [21] Freeman D, Nordyke RJ, Isonaka S, et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 2005;99:1311–18.
- [22] Salome CM, Munoz PA, Berend N, Thorpe CW, Schachter LM, King GG. Effect of obesity on breathlessness and airway responsiveness to methacholine in non-asthmatic subjects. Int J Obes 2007; 23 October [Epub ahead of print].
- [23] Baum CL. The effects of cigarette costs on BMI and obesity. Health Econ 2008;4 February [Epub ahead of print].

- [24] Calverley PM, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D. Development of a population-based screening questionnaire for COPD. COPD 2005;2:225–32.
- [25] Geijer RM, Sachs AP, Verheij TJ, Lammers JW, Salome PL, Hoes AW. Are patient characteristics helpful in recognizing mild COPD (GOLD I) in daily practice? Scand J Prim Health Care 2006;24:237–42.
- [26] Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundback B. Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. Chest 2005;127:1544–52.
- [27] Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;6:98.
- [28] Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002;166:329–32.